

(11) Publication number:

0 039 051
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 81103066.7

(22) Date of filing: 23.04.81

(51) Int. Cl.³: **C 07 D 209/28**


C 07 C 103/44, C 07 C 103/82
C 07 C 147/14, C 07 D 207/20
C 07 D 207/32, C 07 D 209/26
C 07 D 209/46, C 07 D 211/14
C 07 D 213/80, C 07 D 233/06

(30) Priority: 24.04.80 US 143520

(43) Date of publication of application;
04.11.81 Bulletin 81/44(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: MERCK & CO. INC.
126, East Lincoln Avenue P.O. Box 2000
Rahway, New Jersey 07065(US)(72) Inventor: Sloan, Kenneth B.
RR 1 Box 71B
Eudora Kansas 66025(US)(72) Inventor: Little, Roy
3620 Southwest Archer Road No. CA7
Gainesville Florida 32608(US)(74) Representative: Abitz, Walter, Dr.-Ing. et al,
Abitz, Morf, Gritschneider P.O. Box 86 01 09
D-8000 München 86(DE)

(54) Mannich-base hydroxamic acid prodrugs for the improved delivery of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them.

(57) Novel prodrug forms of known non-steroidal anti-inflammatory agents and a process for preparing them are disclosed, said prodrugs having the structural formula



wherein R-C-

$$\begin{array}{c}
 | \\
 \text{O}
 \end{array}$$

is the acyl residue of a non-steroidal anti-inflammatory agent containing a carboxylic acid function; R₁ and R₂ each represent alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, and alkynylaryl, and substituted derivatives of the above groups; or R₁ and R₂ are combined so that -NR₁R₂ together represent the residue of a heterocyclic compound containing one secondary nitrogen atom; R₃ is

hydrogen, R₁, O

-CH₂OCOR'₁, -CH₂ONO₂, pyridyl, furyl, cyano, carbamyl, alkyl carbamyl, and dialkylcarbamyl; R'₁ is any radical encompassed by the definition of R₁ above; or a non-toxic pharmaceutically acceptable acid addition salt or oxide thereof.

These compounds are characterized as being more readily bioavailable, less irritating to topical and gastric mucosal membranes, and more permeable through topical membranes than are the "parent" nonsteroidal anti-inflammatory drugs from which they are derived.

EP 0 039 051 A2

1

TITLE OF THE INVENTION

5 MANNICH-BASE HYDROXAMIC ACID PRODRUGS FOR THE IMPROVED
DELIVERY OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS,
A PROCESS FOR PREPARING AND A PHARMACEUTICAL
COMPOSITION CONTAINING THEM.

10

TECHNICAL FIELD OF THE INVENTION

The present invention relates to novel and
useful derivatives of non-steroidal anti-inflammatory
drugs containing a carboxylic acid function. In
particular, the present invention relates to novel
15 forms of these non-steroidal anti-inflammatory drugs
characterized as being (1) more readily bioavailable;
(2) less irritating to topical and gastric mucosal
membranes; and (3) more permeable through topical

20

25

30

35

membranes such as the ophthalmic membrane, skin, and the like, when administered orally or topically to warm-blooded animals than are the non-steroidal anti-inflammatory drugs from which they are derived.

5 For the purposes of this specification, the term "prodrug" denotes a derivative of a known and proven prior art non-steroidal anti-inflammatory compound (e.g., indomethacin, sulindac, naproxen, or the like), which derivative, when administered to a
10 warm-blooded animal, "cleaves" in such a manner as to release the proven drug form at its target site or sites of activity. The enzymatic and/or chemical hydrolytic "cleavage" of the compounds of the instant invention occurs in such a manner such that the proven
15 drug form (the conventional non-steroidal anti-inflammatory agent) is released while the remaining "cleaved" moiety remains nontoxic and is metabolized in such a manner that nontoxic-metabolic products are produced.

20

20 BACKGROUND OF THE PRIOR ART

Usually, the un-ionized form of a drug is absorbed more efficiently than its ionic species. In the case of non-steroidal anti-inflammatory drugs containing the carboxylic acid functional group such as
25 indomethacin, sulindac, naproxen and the like, the carboxylic acid is significantly ionized at physiological pH. The result is that such non-steroidal anti-inflammatory drugs are poorly absorbed through lipid-water membrane barriers and are
30 irritating. Thus, an object of the present invention is to provide a class of derivatives of non-steroidal

1 wherein R, R₁, R₂ and R₃ are defined as above and,
if desired, preparing a non-toxic pharmaceutically
acceptable acid addition salt or oxide thereof in
a manner known per se.

5

2. A process according to Claim 1 wherein
R-C- is the acyl residue of a non-steroidal anti-



inflammatory agent selected from a group consisting of

10

(1) indomethacin;

(2) sulindac;

(3) naproxen;

(4) fenoprofan;

(5) ibuprofen;

15

(6) tolmetin;

(7) indoprofen;

(8) fenclozic acid;

(9) ketoprofen,

(10) alcolfenac;

20

(11) bucloxix acid;

(12) voltaren;

(13) cinmentacin;

(14) ibufenac;

(15) furobufen;

25

(16) fenclofenac;

(17) prodolic acid;

(18) pirprofen;

(19) oxoprozin;

(20) fluprofen;

30

(21) flurbiprofen

(22) meclofenamic acid;

(23) flufenamic acid;

(24) cinchophen;

35

(25) clonixin;

- 1 (26) flutiazin;
(27) aspirin;
(28) diflunisal; and
5 (29) mefenamic acid.

3. A process according to Claims 1 or 2 wherein
R₁ and R₂ independently are:

- 10 (1) C₁₋₈ alkyl;
(2) C₂₋₈ alkenyl;
(3) phenyl;
(4) C₅₋₆ cycloalkyl;
(5) C₅₋₆ cycloalkenyl;
15 (6) C₂₋₈ alkynyl;
(7) aryl C₁₋₆ alkyl;
(8) C₁₋₆ alkyl-aryl

or a substituted derivative thereof.

20 4. A process according to Claims 1 or 2 wherein
R₁ and R₂ are combined so that -NR₁R₂ together
represent the residue of a saturated or unsaturated
heterocyclic compound containing one secondary nitrogen
atom.

25 5. A process according to Claim 4 wherein
the residue is that of a saturated monocycle containing
one or more hetero atoms in the ring and optionally
bearing one or more phenyl, benzyl or methyl
30 substituents.

6. A process according to Claim 5 wherein
the residue is selected from the group consisting of
morpholino, 1-pyrrolidinyl, 4-benzyl-1-piperazinyl,
35 4-methyl-1-piperazinyl, piperidino, hexamethyleneimino,

nitro, C_1-C_8 haloalkyl having 1 or more halo substituents, dialkylamino wherein the alkyl portions each contain 1 to 8 carbon atoms, carboxy, dialkylcarbaryl wherein the alkyl portions each contain 1 to 8 carbon atoms, and C_1-C_8 alkylsulfonyl; or R_1 or R_2 are combined so that $-NR_1R_2$ together represent the residue of a saturated or unsaturated heterocyclic compound containing one secondary nitrogen atom; R_3 is selected from the group consisting of

hydrogen, R_1 , $\overset{\text{O}}{\parallel}\text{-C-R}_1$, $-\text{CH}_2\text{OCOR}_1$, $-\text{CH}_2\text{ONO}_2$, pyridyl, furyl, cyano, carbaryl, C_2-C_9 alkylcarbaryl and dialkylcarbaryl wherein the alkyl portions each contain 1 to 8 carbon atoms; R_1 is any radical encompassed by the definition of R_1 above; or a non-toxic pharmaceutically acceptable acid addition salt or oxide thereof.

The term "nontoxic pharmaceutically acceptable acid addition salt" as used herein generally includes the nontoxic acid addition salts of selected compounds of formula (I), formed with nontoxic inorganic or organic acids. For example, the salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycollic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, fumaric, methanesulfonic, toluenesulfonic, and the like.

The term "oxide" as used herein includes the non-toxic pharmaceutically acceptable oxides of selected compounds of formula (I). Usually, the oxides are N-oxides but they may be sulfoxides in the event
5 that $-NR_1R_2$ represents the residue of a sulfur-containing heterocycle. The oxides are prepared by oxidation of the selected compounds of formula (I) with a suitable oxidizing agent, e.g., m-chloroperbenzoic acid or hydrogen peroxide, in an appropriate inert
10 solvent such as dichloromethane, benzene or chloroform.

The term "acyl residue" as used herein with respect to any non-steroidal anti-inflammatory agent containing a carboxylic acid function is intended to represent that portion of the anti-inflammatory
15 compound which remains after removal of the -OH from the -COOH portion of the molecule.

The chemical structure of the non-steroidal anti-inflammatory drugs whose acyl residues are encompassed by formula (I) is not critical, so long as
20 those drugs contain a carboxylic acid function. Suitable anti-inflammatory agents from which the instant prodrugs are derived include, but are not limited to, indomethacin, aspirin, naproxen, fenoprofen, sulindac, ibuprofen, tolmetin, difunisal,
25 flurbiprofen, indoprofen, mefanamic acid, fenclozic acid, ketoprofen, alcolfenac, bucloxix acid, meclofenamic acid, flufenamic acid, cinchophen, voltaren, cinmetacin, ibufenac, furobufen, fenclofenac, prodolic acid, piroprofen, oxoprozin, clonixin,
30 fluprofen and flutiazin.

With respect to the radicals encompassed by R_1 , R_2 and $-NR_1R_2$ in formula (I) and throughout this specification, the following definitions are applicable:

- 5 The expression "the residue of a saturated or unsaturated heterocyclic compound containing one secondary nitrogen atom" as used herein is intended to indicate the portion of the heterocyclic compound which remains after removal of the hydrogen atom from the
- 10 secondary nitrogen. Thus, the term "saturated or unsaturated heterocyclic compound containing the secondary nitrogen atom" encompasses saturated monocycles containing one or more hetero atoms in the ring, optionally bearing one or more substituents such
- 15 as phenyl, benzyl and methyl; and unsaturated one and two ring systems containing one or more double bonds and one or more ring hetero atoms, optionally substituted with one or more methyl groups. In every case, the substituents and double bonds, if any, must
- 20 be located such that the parent heterocyclic compound from which the residue $-NR_1R_2$ is derived is a compound of the formula HNR_1R_2 , i.e., the parent compound invariably contains one N which is a secondary nitrogen atom. When the parent heterocycle contains
- 25 more than one nitrogen atom, one nitrogen must be a secondary nitrogen and any other nitrogen must be tertiary. In any case, the parent compound can contain other hetero atoms, e.g., sulfur and/or oxygen. Illustrative of residues of saturated monocyclic
- 30 heterocyclics which are encompassed by the $-NR_1R_2$

term are morpholino, perhydro-1,2,4-oxathiazin-4-yl, 1-pyrrolidinyl, 4-benzyl-1-piperazinyl, 4-methyl-1-piperazinyl, piperidino, hexamethyleneimino, 4-phenylpiperidino, 2-methyl-1-pyrazolidinyl, 5 3-methyl-1-imidazolidinyl, 4-benzylpiperidino and 4-phenyl-1-piperazinyl. Exemplary of residues of unsaturated one and two ring heterocyclic systems represented by $-NR_1R_2$ are radicals such as 1-imidazolyl, 1-pyrrolyl, 1-pyrazolyl, 1-indolinyl, 10 2-isoindolinyl, 1-indolyl, 2-isoindolyl, 1H-indazol-1-yl, and 7-purinyl; and radicals derived from compounds such as pyrazoline, pyrroline and imidazoline wherein there is one secondary nitrogen atom, e.g., radicals of the type

15



20

and the like. In addition, any of the aforesaid 25 unsaturated one and two ring heterocycles can be optionally substituted with one or more methyl groups.

The term "aryl" as used herein can be exemplified by phenyl and naphthyl.

In addition, here and throughout this 30 specification, the following examples are applicable: The alkyl radicals include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl and octyl and th

branched-chain isomers thereof, as well as their straight and branched-chain higher homologues in the instances where "alkyl" can contain more than 8 carbon atoms. The alkenyl and alkynyl radicals may be
5 straight or branched-chain, for example, vinyl, propenyl, butenyl, ethynyl, propynyl, butynyl, and the like. The cycloalkyl and cycloalkenyl radicals are exemplified by cyclopentyl, cyclohexyl and cyclopentenyl. The aralkyl, aralkenyl and aralkynyl
10 radicals are of the type

-alkylene-aryl

-alkenylene-aryl








and

-alkynylene-aryl


15 wherein aryl is as defined above and the alkylene, alkenylene and alkynylene moieties contain up to 20 carbon atoms (preferably up to 6 carbon atoms) and can be straight or branched-chain. The alkylene moieties are typified by methylene, ethylene, propylene,
20 trimethylene, 1,2-butylene, 2,3-butylene, tetramethylene and the like. Exemplary of the contemplated alkenylene and alkynylene moieties are vinylene, ethynylene, butenylene and butynylene. Additionally, the alkoxy, alkanoyl, alkanoyloxy,
25 carbalkoxy, alkylthio, dialkylamino, dialkylcarbamyl, alkylsulfonyl and alkylcarbamyl radicals are of the type

-10-

IX 072



and



respectively, wherein the alkyl group in each instance contains 1 to 8 carbon atoms.

DETAILED DESCRIPTION OF THE INVENTION

While all of the compounds encompassed by formula (I) above essentially satisfy the objectives of the present invention, the following selected compounds are preferred:

- 5 1. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic acid.
2. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol--3-yl]-N-(N',N'-diethylaminomethyl)aceto-
10 hydroxamic acid.
3. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(4-methylpiperazin-1-yl)methyl]-acetohydroxamic acid.
4. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-
15 methylindol-3-yl]-N-(piperidinomethyl)acetohydroxamic acid.
5. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(pyrrolidin-1-yl)methyl]acetohydroxamic acid.
- 20 6. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol--3-yl]-N-(N',N'-dicyclohexylaminomethyl)acetohydroxamic acid.
7. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[pyrrol-1-yl)methyl]acetohydroxamic
25 acid.
8. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(indol-1-yl)methyl]acetohydroxamic acid.
9. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-
30 methylindol-3-yl]-N-[(isoindol-2-yl)methyl]acetohydroxamic acid.

10. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(purin-7-yl)methyl]acetohydroxamic acid.
- 5 11. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N',N'-dimethylaminomethyl)acetohydroxamic acid.
12. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N',N'-diisopropylaminomethyl)acetohydroxamic acid.
- 10 13. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N',N'-dipentylaminomethyl)acetohydroxamic acid.
14. α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N',N'-dioctylaminomethyl)acetohydroxamic acid.
- 15 15. α -[cis-5-Fluoro-2-methyl-1-[4'-(methylsulfinyl)-benzylidene]inden-3-yl]-N-(piperidinomethyl)acetohydroxamic acid.
16. α -[cis-5-Fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl]-N-[(N'-benzyl-N'-phenyl)aminomethyl]acetohydroxamic acid.
- 20 17. α -[cis-5-Fluoro-2-methyl-1-[4'-(methylsulfinyl)-benzylidene]inden-3-yl]-N-(morpholinomethyl)acetohydroxamic acid.
- 25 18. α -[cis-5-Fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl]-N-[(imidazol-1-yl)methyl]acetohydroxamic acid.
19. α -(6-Methoxynaphthalen-2-yl)- α -methyl-N-(N',N'-diethylaminomethyl)acetohydroxamic acid.
- 30 20. α -Methyl- α -(3-phenoxy)phenyl-N-(piperidinomethyl)acetohydroxamic acid.

21. α -Methyl- α -(3-phenoxy)phenyl-N-
[(N'-benzyl-N'-phenyl)aminomethyl]acetohydroxamic acid.
22. α -Methyl- α -(3-phenoxy)phenyl-N-
(morpholinomethyl)acetohydroxamic acid.
- 5 23. α -Methyl- α -(3-phenoxy)phenyl-N-
[(imidazol-1-yl)methyl]acetohydroxamic acid.
24. α -Methyl- α -[4-(2'-methylpropyl)]-
phenyl-N-(morpholinomethyl)acetohydroxamic acid.
25. α -Methyl- α -[4-(2'-methylpropyl)]-
10 phenyl-N-(piperidinomethyl)acetohydroxamic acid.
26. α -[1-Methyl-5-(p-toluoyl)pyrrol-2-
yl]-N-(N',N'-diethylaminomethyl)acetohydroxamic acid.
27. α -Methyl- α -[4-(1'-oxoisoindol-2'-yl)]-
phenyl-N-(piperidinomethyl)acetohydroxamic acid.
- 15 28. α -Methyl- α -[4-(1'-oxoisoindol-2'-
yl)]phenyl-N-(morpholinomethyl)acetohydroxamic acid.

It will be apparent to those skilled in the art that the preferred compounds listed above are derived from indomethacin, sulindac, naproxen, 20 fenoprofen, ibuprofen, tolmetin and indoprofen. Other suitable anti-inflammatory agents from which the instant prodrugs can be derived include, but are not limited to, fenclozic acid, ketoprofen, alcolfenac, bucloxic acid, meclofenamic acid, flufenamic acid, 25 cinchophen, voltaren, cinmetacin, ibufenac, furobufen, fenclofenac, prodolic acid, pirofen, oxoprozin, clonixin, fluprofen, flutiazin, aspirin, diflunisal, flurbiprofen and mefenamic acid.

The novel prodrugs of formula (I) can be prepared by first reacting the acid chloride of a non-steroidal anti-inflammatory agent of the formula



5

wherein $\begin{array}{c} \text{R}-\text{C}- \\ \parallel \\ \text{O} \end{array}$ is as hereinbefore defined, with

hydroxylamine, suitably employed in the form of its
10 hydrochloride $\text{H}_2\text{NOH}\cdot\text{HCl}$. The reaction is conveniently conducted in the presence of a suitable base, e.g., potassium carbonate, in an appropriate organic solvent or mixture of solvents, e.g., diethyl ether/tetrahydrofuran. The resultant intermediate is
15 of the formula



20

wherein $\begin{array}{c} \text{R}-\text{C}- \\ \parallel \\ \text{O} \end{array}$ is as hereinbefore defined. The

hydroxamic acid of formula (III) is then reacted with formaldehyde or other aldehyde of the type R_3CHO wherein R_3 is as defined above, and a secondary amine of the formula

25



30

wherein R_1 , R_2 and $-NR_1R_2$ are defined as before, to afford the desired prodrug of formula (I). The reaction is carried out in an appropriate organic solvent such as tetrahydrofuran, and the formaldehyde
5 can be conveniently introduced into the reaction mixture in the form of formalin (a solution of about 37% by weight of formaldehyde gas in water, usually with 10-15% methanol added to prevent polymerisation).

The acid chloride starting material of formula
10 (II) above is prepared in known manner from the corresponding nonsteroidal anti-inflammatory agent $R-C(=O)OH$, wherein $R-C(=O)-$ is defined as above, typically

by treatment of that acid with thionyl chloride.

15 Without further elaboration, it is believed that one of ordinary skill in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the following preferred embodiments are to be construed as merely illustrative
20 and not limitative of the remainder of the specification and claims in any way whatsoever.

EXAMPLE 1

The Preparation of the Acid Chloride of 1-(4'-Chloro-benzoyl)-5-methoxy-2-methyl-3-indolylacetic Acid, i.e.,
25 Indomethacin Acid Chloride

To 9.00 g (0.0757 mol) of thionyl chloride in 400 ml of dichloromethane were added 5.55 g (0.076 mol) of dimethylformamide in 100 ml of dichloromethane. After 10 minutes at room temperature, the above
30 solution was allowed to react with a dichloromethane (100 ml) suspension containing 25.7 g (0.072 mol) of

indomethacin. The resulting faintly orange solution was immediately concentrated in vacuo to give a light yellow residue which was triturated with 500 ml of ether overnight. The precipitate was then removed by
5 filtration and dried to give 16.7 g (mp 124-126°C., 61% yield) of the desired indomethacin acid chloride: IR (KBr) 1790 and 1675 cm^{-1} (s) (C=O); NMR (CDCl_3) δ 7.60 (AB quartet, 4, $J = 9$ Hz, $\Delta_{AB} = 11$ Hz, aromatic H), 7.0 - 6.55 (m, 3, aromatic H), 4.17 (s, 2,
10 CH_2COCl) 3.83 (s, 3, O- CH_3) and 2.41 (s, 3, $\text{CH}_3\text{-C=C}$).

Anal. Calcd for $\text{C}_{19}\text{H}_{15}\text{Cl}_2\text{NO}_3$: C, 60.65; H, 4.02; N, 3.72. Found: C, 60.59; H, 4.08; N, 3.50.

EXAMPLE 2

15 The Preparation of α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetohydroxamic Acid, i.e.,
Indomethacin Hydroxamic Acid

Hydroxylamine hydrochloride (7.47 g, 0.107 mole) and potassium carbonate (14.84 g, 0.107 mole)
20 were dissolved in 20 ml of H_2O . 1000 ml of ethyl ether were added and the resulting suspension was stirred for 10 minutes. Then, a suspension of indomethacin acid chloride (40.46 g, 0.107 mole) in 600 ml of tetrahydrofuran was added and the reaction
25 mixture was stirred overnight. The suspension was then filtered and the residue was washed twice with ethyl ether, then was suspended in 600 ml of boiling tetrahydrofuran and filtered while hot. The filtrate was concentrated to 150 ml and allowed to crystallize
30 at room temperature overnight. The crystals were

removed by filtration and washed twice with ethyl ether to give 18.72 g (mp 147-150°C, 47% yield) of slightly yellow fibrous crystals which were shown to be the pure product:

- 5 NMR (DMSO- d_6) δ 10.65 (s, 1, NOH), 8.8 (bm, 1, -NHOH), 7.67 (s, 4, $\text{-C}_6\text{H}_4\text{Cl}$), 7.22 - 6.6 (m, 3, $\text{-C}_6\text{H}_3\text{OCH}_3$), 3.80 (s, 3, -OCH_3), 3.42 (s, 2, $\text{O=CCH}_2\text{-}$), 2.28 (s, 3, CCH_3), IR (KBr) 3300-3150 cm^{-1} (b) (NO-H), 1650, 1630 cm^{-1} (N-C=O).
- 10 Anal. Calcd for $\text{C}_{19}\text{H}_{17}\text{ClN}_2\text{O}_4$: C, 61.21; H, 4.60; N, 7.52. Found: C, 61.32; H, 4.80; N, 7.00.
- Similarly prepared from their acid chlorides are the hydroxamic acid derivatives of sulindac, naproxen, fenoprofen, ibuprofen, tolmetin and
- 15 indoprofen. The corresponding hydroxamic acid derivatives of the other anti-inflammatory agents specified herein can be prepared in like manner.

EXAMPLE 3

- 20 The Preparation of α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic Acid

Formalin (0.82 g) was mixed with morpholine (0.71 g, 0.0082 mole) in 90 ml of tetrahydrofuran, then indomethacin hydroxamic acid (3.04 g, 0.0082 mole) was

25 added. The resulting suspension was heated in a hot water bath until all the solids had dissolved, then the reaction vessel was stoppered and the solution was allowed to cool overnight. During that time, a small amount of crystals formed. The solution was diluted to

30 250 ml with cyclohexane and allowed to stand for 2

hours. The crystals which formed were removed by filtration and washed twice with cyclohexane, then dried in vacuo (60°C for 8 hours) to give 2.01 g (mp 179-180°C, 68% yield) of white powder which was pure product: NMR (DMSO- d_6) δ 7.70 (s, 4, $-C_6H_4Cl$), 7.10 - 6.70 (m, 3, 2OC_6H_3), 4.35 (s, 2, NCH_2N), 3.84 (s, 2, $-COCH_2-$), 3.77 (s, 3, $-OCH_3$), 3.26 (m, 4, $O(CH_2)_2-$), 2.6 (m, 4, $N(CH_2)_2-$), 2.24 (s, 3, $C-CH_3$); IR (KBr), 3150 cm^{-1} (bw) ($-NO-H$), 2900 cm^{-1} (C-H), 1660 cm^{-1} (s) (NC=O), 1600 cm^{-1} (s) (HONC=O).

Anal. Calcd for $C_{24}H_{25}ClN_3O_5$: C, 61.21; H, 5.35; N, 8.92. Found: C, 61.44; H, 5.68; N, 8.50.

EXAMPLE 4

15 The Preparation of α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(4-methylpiperazin-1-yl)methyl]-acetohydroxamic Acid

This preparation was carried out analogously to the procedure of Example 3 above, using 3.31 g (0.0089 mole) of indomethacin hydroxamic acid, 0.89 g of formalin and 0.89 g (0.0089 mole) of N-methylpiperazine in 90 ml of tetrahydrofuran. Crystallization of the product was accomplished by concentrating the reaction solution to 30 ml and then diluting that solution to 100 ml with cyclohexane. The resultant cloudy solution was allowed to crystallize over 3 days' time, then the crystals were removed by filtration and washed twice with a mixture of hexanes to give 3.53 g (82% yield, mp 143-145°C) of off-white, powdery crystalline product: NMR (DMSO- d_6) δ 7.66

(s, 4, $-\text{C}_6\text{H}_4\text{Cl}$), 7.10 - 6.60 (m, 3, $-\text{OC}_6\text{H}_3-$),
 4.33 (s, 2, $-\text{NCH}_2\text{N}$), 3.48 (s, 2, COCH_2-), 3.41 (s,
 3, $-\text{OCH}_3$), 2.7 - 2.0 (m, 8, $-\text{N}(\text{CH}_2\text{CH}_2)_2\text{N}-$),
 2.19 (s, 3, NCH_3), 2.16 (s, 3, $\text{C}-\text{CH}_3$); IR (KBr),
 5 2800-3000 cm^{-1} (m) (C-H), 1665 cm^{-1} (s) (NC=O), 1600
 cm^{-1} (s) (HONC=O).

Anal. Calcd for $\text{C}_{25}\text{H}_{29}\text{ClN}_4\text{O}_4$: C, 61.91;
 H, 6.03; N, 11.56. Found: C, 62.07; H, 6.00; N, 11.21.

EXAMPLE 5

10 The Preparation of α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N', N'-diethylaminomethyl)-acetohydroxamic Acid

This preparation and crystallization were
 15 carried out analogously to the procedures of Examples 3
 and 4 above, using 3.15 g (0.0085 mole) of indomethacin
 hydroxamic acid, 0.85 g of formalin and 0.62 (0.0085
 mole) of diethylamine in 70 ml of tetrahydrofuran.
 After 3 days of crystallizing, the crystalline product
 20 was removed by filtration and washed twice with a
 mixture of hexanes to give 3.08 g (79% yield, mp
 134-137°C) of white powder: NMR (CDCl_3) δ 8.03 (bs,
 1, NOH), 7.7 - 6.7 (m, 7, aromatic-H), 4.42 (s, 2,
 NCH_2N), 3.85 (s, 2, $-\text{COCH}_2$), 3.82 (s, 3, $-\text{OCH}_3$),
 25 2.65 (q, 4, $J=8$ Hz, NCH_2), 2.35 (s, 3, $\text{C}-\text{CH}_3$), 1.04
 (t, 6, $J=8$ Hz, NCH_2CH_3); IR (KBr) 3150 cm^{-1} (w)

(NO-H), 2800-3000 cm^{-1} (w) (C-H), 1667 cm^{-1}
 (s) (NC=O), 1600 cm^{-1} (s) (HONC=O).











Anal. Calcd for $\text{C}_{24}\text{H}_{28}\text{ClN}_3\text{O}_4$: C, 62.94;
 30 H, 6.16; H, 9.18. Found: C, 62.51; H, 6.18; N, 8.90.

In similar fashion, the other compounds of the present invention can be prepared with similar success by merely following the preceding examples and substituting the appropriate generically and/or specifically described reactants and/or operating conditions of this invention for those of the preceding examples. Thus, the following additional compounds can be prepared by following the above reaction scheme:

COMPOUNDS OF FORMULA (I)

Example Number	$\begin{array}{c} \text{R}-\text{C}- \\ \parallel \\ \text{O} \end{array}$	R_3	$\begin{array}{c} \text{R}_1 \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{R}_2 \end{array}$
6		H	$\begin{array}{c} \text{CH}_3 \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{CH}_3 \end{array}$
7		H	$\begin{array}{c} \text{C}_5\text{H}_{11} \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{C}_5\text{H}_{11} \end{array}$
8		H	$\begin{array}{c} \text{C}_8\text{H}_{17} \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{C}_8\text{H}_{17} \end{array}$

Example Number	$\begin{array}{c} \text{R}-\text{C}- \\ \\ \text{O} \end{array}$	R_3	$\begin{array}{c} \text{R}_1 \\ \diagup \\ -\text{N}- \\ \diagdown \\ \text{R}_2 \end{array}$
9		H	
10		H	
11		H	
12		H	
13		H	

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$-\text{N}(\text{R}_1)(\text{R}_2)$
14		H	
15		H	
16		H	
17		H	
18		H	

Example Number	R-C- O	R ₃	-N $\begin{matrix} R_1 \\ R_2 \end{matrix}$
19		H	
20		H	
21		H	
22		H	
23		H	
24		H	













-24-

IX 072

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$-\text{N} \begin{matrix} \text{R}_1 \\ \text{R}_2 \end{matrix}$
25		H	
26		H	
27		H	
28		H	
29		H	
30		H	

-25-

IX 072

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$\text{N}(\text{R}_1)(\text{R}_2)-$
31		H	
32		H	
33		H	
34		H	
35		H	
36		H	

-26-

IX 072

Example Number	$\begin{array}{c} \text{R}-\text{C}- \\ \parallel \\ \text{O} \end{array}$	R_3	$\begin{array}{c} \text{R}_1 \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{R}_2 \end{array}$
37		H	
38		H	
39		H	
40		H	
41		H	
42		H	
43		H	

-27-











IX 072

Example Number	$\begin{array}{c} \text{R}-\text{C}- \\ \parallel \\ \text{O} \end{array}$	R_3	$\begin{array}{c} \text{R}_1 \\ \diagup \\ -\text{N} \\ \diagdown \\ \text{R}_2 \end{array}$
44		H	
45		H	
46		H	
47		H	
48		H	
49		H	
50		H	

-28-

IX 072

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$-\text{N}(\text{R}_1)(\text{R}_2)$
51		H	
52		H	
53		H	
54		H	
55		H	

Example Number	$\text{R}-\text{C}-$ O	R_3	$\text{-N}-$ R_1 R_2
56		H	
57		H	
58		H	
59		H	
60		H	














-30-

IX 072

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$-\text{N} \begin{matrix} \text{R}_1 \\ \text{R}_2 \end{matrix}$
61		H	
62		H	
63		H	
64		H	
65		H	

-31-

IX 072

Example Number	R-C- 	R ₃	
66		H	
67		H	
68		H	
69		-CCl ₃	
70			

-32-

IX 072

Example Number	$\text{R}-\text{C}(=\text{O})-$	R_3	$\text{N} \begin{matrix} \nearrow \text{R}_1 \\ \searrow \text{R}_2 \end{matrix}$
71			
72			
73			
74			
75		H	$\text{N} \begin{matrix} \nearrow (i-\text{C}_3\text{H}_7) \\ \searrow (i-\text{C}_3\text{H}_7) \end{matrix}$

The anti-inflammatory activity of the prodrugs of formula (I) is evident from the results of the mouse ear assay [C. G. Van Arman, Clin. Pharm. Ther., 16, 900 (1974)] obtained when representative species of the invention were employed as the test compound. Details of the mouse ear assay are as follows:

The test animal was the male ddY strain mouse (20-25 grams each). Solutions of the test compound in acetone containing 2% croton oil (i.e., a solution containing 98 parts of acetone to 2 parts of croton oil) were prepared for varying concentrations of the test compound. Then, the test animals were anesthetized and 0.05 ml of the selected test solution was applied in 0.025 ml aliquots, one each to the anterior and posterior surface of the right ear of each mouse. Three hours after application, the mice were sacrificed via ether inhalation and both ears were removed from each mouse. Then, one circular section, 8 mm in diameter, was taken from each ear using a leather punch. The increase in weight caused by the irritant was determined by subtracting the weight of the untreated left ear section from that of the right ear section. Drug effects expressed as percent inhibition were determined at each selected concentration (molarity) of each test compound according to the following equation:

$$\% \text{inhibition} = \frac{\text{Mean Weight Increase control} - \text{Mean Weight Increase for treated}}{\text{Mean Weight Increase for control}} \times 100$$

Groups of 15 mice were treated at each dosage level of each test compound. The control group consisted of 30 mice. In the control group, the right

ear of each mouse was treated with the croton oil/acetone solution described above but not containing test compound, while the left ear of each control mouse was untreated.

- 5 Indomethacin, indomethacin hydroxamic acid and the compounds of Examples 3, 4 and 5 were tested according to the mouse ear assay described above. The ED_{50} , that is, the dosage which was effective in reducing the weight of the ear by 50%, was obtained for
 10 each test compound from linear regression analysis of data obtained at 2×10^{-2} , 4×10^{-2} and 8×10^{-2} M dosage levels, i.e., the percent inhibition as calculated above was plotted against concentration and the point at which inhibition was 50% was considered
 15 the ED_{50} for a given compound. The results were as follows:

	<u>TEST COMPOUND</u>	<u>ED_{50} (M)</u>
	Indomethacin	0.061
20	Indomethacin hydroxamic acid	0.096
25	α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-morpholinomethyl)-aceto-hydroxamic acid	0.054
30	α -[1-(4'-Chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-[(4-methylpiperazin-1-yl)-methyl]acetohydroxamic acid	0.027

5 α -[1-(4'-Chlorobenzoyl)-
 5-methoxy-2-methyl-
 indol-3-yl]-N-(N',
 N'-diethylamino-
 methyl)-acetohydroxamic
 acid 0.041

The compounds of the present invention are conveniently administered to warm-blooded animals via conventional oral or topical administration, most
10 conveniently by combining the selected compound with any suitable nontoxic pharmaceutically acceptable oral or topical inert carrier material. Such carrier materials are well known to those skilled in the art of oral and topical pharmaceutical formulations. For
15 those not skilled in the art, reference is made to the text entitled, "REMINGTON'S PHARMACEUTICAL SCIENCES" (Fourteenth Edition), 1970. In a typical preparation for oral administration, e.g., tablet or capsule, any one of the compounds of the instant invention is
20 combined in an anti-inflammatory effective amount with any oral nontoxic pharmaceutically acceptable inert carrier such as lactose, starch (pharmaceutical grade), dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar. Additionally when required,
25 suitable binders, lubricants, disintegrating agents and coloring agents can also be included. Typical binders include starch, gelatin, sugars such as sucrose, molasses and lactose, natural and synthetic gums such as acacia, sodium alginate, extract of Irish moss,
30 carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polyethylene glycol, ethylcellulose and waxes. Typical lubricants for use in these dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium

chloride, leucine and polyethylene glycol. Suitable disintegrators can include, without limitation, starch, methylcellulose, agar, bentonite, cellulose, wood products, alginic acid, guar gum, citris pulp, 5 carboxymethylcellulose and sodium lauryl sulfate. If desired, a conventional pharmaceutically acceptable dye can be incorporated into the dosage unit form, i.e., any of the standard FD&C dyes.

Similarly, in a typical formulation for 10 topical application, any one of the compounds of the instant invention is combined with a topical vehicle such as triacetin, such that the active ingredient is present in an anti-inflammatory effective amount. The preparation is simply applied topically to the inflamed 15 area, whereby the therapeutically active compound is dermally absorbed and "cleaved" to release the parent moiety at the site of inflammation.


Naturally, the therapeutic dosage range for the compounds of the instant invention will vary with 20 the size and needs of the patient. However, generally speaking, the following dosage guidelines will suffice. On an oral basis, the therapeutic dose required for a compound of the instant invention will generally, on a molecular basis, mimic that for the 25 parent conventional non-steroidal moiety (e.g., indomethacin, aspirin, naproxen, or the like). On a topical basis, application of an 0.01% to 2.5% concentration of a compound of the instant invention (in a suitable topical carrier material) to the site of 30 inflammation should suffice.

From the foregoing description, one of ordinary skill in the art can easily ascertain the

essential characteristics of the instant invention, and without departing from the spirit and scope thereof, can make various changes and/or modifications of the instant invention to adapt it to various usages and
5 conditions. As such, these changes and/or modifications are properly, equitably and intended to be, within the full range of equivalence of the following claims.

WHAT IS CLAIMED IS:

1. A compound of the formula



wherein $\text{R}-\text{C}-$ is the acyl residue of a non-steroidal
 $\begin{array}{c} \text{O} \\ || \\ \text{O} \end{array}$
 15 anti-inflammatory agent containing a carboxylic acid
 function; R_1 and R_2 , which can be the same or
 different, each represent a member selected from the
 group consisting of alkyl of 1 to 20 carbon atoms;
 20 alkenyl of 2 to 20 carbon atoms; aryl of 6 to 10 carbon
 atoms; cycloalkyl of 3 to 8 carbon atoms; cycloalkenyl
 of 4 to 8 carbon atoms; alkynyl of 2 to 20 carbon
 atoms; aralkyl, alkaryl, aralkenyl, aralkynyl,
 alkenylaryl, and alkynylaryl, wherein the alkyl,
 25 alkenyl, alkynyl, and aryl portions are defined as
 above; and substituted derivatives of the above-defined
 alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl,
 alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl,
 alkenylaryl and alkynylaryl radicals, said derivatives
 30 having one or more substituents each of which are
 selected from the group consisting of C_1-C_8
 alkyl, C_1-C_8 alkoxy, C_1-C_8 alkanoyl, C_1-C_8

5 alkanoyloxy, halo, cyano, C₂-C₉ carbalkoxy
 C₁-C₈ alkylthio, nitro, C₁-C₈ haloalkyl having
 1 or more halo substituents, dialkylamino wherein the
 alkyl portions each contain 1 to 8 carbon atoms,
 10 carboxyl, dialkylcarbaryl wherein the alkyl portions
 each contain 1 to 8 carbon atoms, and C₁-C₈
 alkylsulfonyl or R₁ and R₂ are combined so that
 -NR₁R₂ together represent the residue of a
 saturated or unsaturated heterocyclic compound
 15 containing one secondary nitrogen atom; R₃ is
 selected from the group consisting of hydrogen, R₁',
 $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}-\text{C}-\text{R}_1' \end{array}$, -CH₂OCOR₁', -CH₂ONO₂, pyridyl, furyl,
 cyano, carbaryl, C₂-C₉ alkylcarbaryl, and
 20 dialkylcarbaryl wherein the alkyl portions each contain
 1 to 8 carbon atoms; R₁' is any radical encompassed by
 the definition of R₁' above; or a non-toxic
 pharmaceutically acceptable acid addition salt or oxide
 thereof.

20

2. A compound according to Claim 1 wherein

$\begin{array}{c} \text{O} \\ \parallel \\ \text{R}-\text{C}- \end{array}$ is the acyl residue of a non-steroidal anti-

inflammatory agent selected from a group consisting of

25

(1) indomethacin;

(2) sulindac;

(3) naproxen;

(4) fenoprofan;

(5) ibuprofen;

30

(6) tolmetin;

(7) indoprofen;

(8) fenclozic acid;

(9) ketoprofen,

- 5 (10) alcolfenac;
(11) bucloxic acid;
(12) voltaren;
(13) cinmentacin;
(14) ibufenac;
(15) furobufen;
(16) fenclofenac;
(17) prodolic acid;
10 (18) pirprofen;
(19) oxoprozin;
(20) fluprofen;
(21) flurbiprofen
(22) meclofenamic acid;
(23) flufenamic acid;
15 (24) cinchophen;
(25) clonixin;
(26) flutiazin;
(27) aspirin;
(28) diflunisal; and
20 (29) mefenamic acid.

3. A compound according to Claims 1. or 2. wherein R_1 and R_2 independently are:

- 25 (1) C_{1-8} alkyl;
(2) C_{2-8} alkenyl;
(3) phenyl;
(4) C_{5-6} cycloalkyl;
(5) C_{5-6} cycloalkenyl;
(6) C_{2-8} alkynyl;
30 (7) aryl C_{1-6} alkyl;
(8) C_{1-6} alkyl-aryl

or a substituted derivative thereof.

4. A compound according to Claims 1 or 2 wherein R_1 and R_2 are combined so that $-NR_1R_2$ together represent the residue of a saturated or unsaturated heterocyclic compound containing one secondary nitrogen
5 atom.

5. A compound according to Claim 4 wherein the residue is that of a saturated monocycle containing one or more hetero atoms in the ring and optionally bearing one or more phenyl, benzyl or methyl
10 substituents.

6. A compound according to Claim 5 wherein the residue is selected from the group consisting of morpholino, 1-pyrrolidinyl, 4-benzyl-1-piperazinyl, 4-methyl-1-piperazinyl, piperidino, hexamethyleneimino,
15 4-phenylpiperidino, 2-methyl-1-pyrazolidinyl, 3-methyl-1-imidazolidinyl, 4-benzylpiperidino and 4-phenyl-1-piperazinyl.

7. A compound according to Claim 4 wherein the residue is that of an unsaturated one or two ring
20 system containing one or more double bonds and one or more ring hetero atoms, optionally substituted with one or more methyl groups.

8. A compound according to Claim 7 wherein the residue is selected from the group consisting of
25 1-imidazolyl, 1-pyrrolyl, 1-pyrazolyl, 1-indolinyl, 2-isoindolinyl, 1-indolyl, 2-isoindolyl,

1H-indazol-1-yl, 7-purinyl, pyrazolines, pyrrolines, and imidazolines.

9. A compound according to any one of Claims 1 to 8 wherein R_3 is hydrogen, alkyl, substituted alkyl having one

5

or more halo substituents, alkyl-C(=O)- or aryl-C(=O)-.

10. The compound according to Claim 1 which is selected from a group consisting of

10

(1) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(morpholinomethyl)acetohydroxamic acid;

(2) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(N',N'-diethylaminomethyl)acetohydroxamic acid;

15

(3) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(4-methylpiperazin-1-yl)methyl]acetohydroxamic acid;

20

(4) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-(piperidinomethyl)acetohydroxamic acid;

(5) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-N-[(pyrrolidin-1-yl)methyl]acetohydroxamic acid;

- 5 (6) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dicyclohexylamino-methyl)acetohydroxamic acid;
- (7) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-[(pyrrol-1-yl)methyl]aceto-hydroxamic acid;
- 10 (8) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-[(indol-1-yl)methyl]aceto-hydroxamic acid;
- (9) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-[(isoindol-2-yl)methyl]aceto-hydroxamic acid;
- 15 (10) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-[(purin-7-yl)methyl]aceto-hydroxamic acid;
- (11) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dimethylaminomethyl)-acetohydroxamic acid;
- 20 (12) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-diisopropylamino-methyl)acetohydroxamic acid;
- (13) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dipentylaminomethyl)-acetohydroxamic acid;

- (14) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dioctylaminomethyl)-acetohydroxamic acid;
- 5 (15) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-(piperidinomethyl)acetohydroxamic acid;
- 10 (16) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-[(N'-benzyl-N'-phenyl)aminomethyl]acetohydroxamic acid;
- (17) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-(morpholinomethyl)acetohydroxamic acid;
- 15 (18) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-[(imidazol-1-yl)methyl]acetohydroxamic acid;
- 20 (19) α -(6-methoxynaphthalen-2-yl)- α -methyl-N-(N',N'-diethylaminomethyl)acetohydroxamic acid;
- (20) α -methyl- α -(3-phenoxy)phenyl-N-(piperidinomethyl)acetohydroxamic acid;
- 25 (21) α -(methyl- α -(3-phenoxy)phenyl-N-[(N'-benzyl-N'-phenyl)aminomethyl]acetohydroxamic acid;

1

(22) α -methyl- α -(3-phen xy)phenyl-N-(m rpholino-
methyl)acetohydroxamic acid;

5

(23) α -methyl- α -(3-phenoxy)phenyl-N-[(imidazol-
1-yl)methyl]acetohydroxamic acid;

10

(24) α -methyl- α -[4-(2'-methylpropyl)]phenyl-N-
(morpholinomethyl)acetohydroxamic acid;

(25) α -methyl- α -[4-(2'-methylpropyl)]phenyl-N-
(piperidinomethyl)acetohydroxamic acid;

15

(26) α -[1-methyl-5-(p-toluoyl)pyrrol-2-yl]-N-
(N',N'-diethylaminomethyl)acetohydroxamic
acid;

20

(27) α -methyl- α -[4-(1'-oxoisoindol-2'-yl)]phenyl
-N-(piperidinomethyl)acetohydroxamic
acid; and

(28) α -methyl- α -[4-(1'-oxoisoindol-2'-yl)]phenyl
-N-(morpholinomethyl)acetohydroxamic acid.

25


11. A pharmaceutical composition of matter
comprising an anti-inflammatory effective amount of a
compound of Claim 1, in combination with a nontoxic
pharmaceutically acceptable inert carrier therefor.

30


12. A process for the preparation of a compound
according to Claim 1 comprising reacting the acid
chloride of a nonsteroidal anti-inflammatory agent of
the formula

35


1



5 with hydroxylamine followed by treatment with an aldehyde of the formula



10 and a secondary amine of the formula



15

wherein R, R₁, R₂ and R₃ are defined according to Claim 1.

20

25


30

35

Claims for Austria


IX 072

1. A process for the preparation of a compound of the formula




wherein $\text{R}-\text{C}(=\text{O})-$ is the acyl residue of a non-steroidal
 15 anti-inflammatory agent containing a carboxylic acid function; R_1 and R_2 , which can be the same or different, each represent a member selected from the group consisting of alkyl of 1 to 20 carbon atoms;
 20 alkenyl of 2 to 20 carbon atoms; aryl of 6 to 10 carbon atoms; cycloalkyl of 3 to 8 carbon atoms; cycloalkenyl of 4 to 8 carbon atoms; alkynyl of 2 to 20 carbon atoms; aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, and alkynylaryl, wherein the alkyl,
 25 alkenyl, alkynyl, and aryl portions are defined as above; and substituted derivatives of the above-defined alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl and alkynylaryl radicals, said derivatives
 30 having one or more substituents each of which are selected from the group consisting of $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkoxy, $\text{C}_1\text{-C}_8$ alkanoyl, $\text{C}_1\text{-C}_8$


1 alkanoyloxy, halo, cyano, C₂-C₉ carbalkoxy
 C₁-C₈ alkylthio, nitro, C₁-C₈ haloalkyl having
 1 or more halo substituents, dialkylamino wherein the
 5 alkyl portions each contain 1 to 8 carbon atoms,
 carboxyl, dialkylcarbonyl wherein the alkyl portions
 each contain 1 to 8 carbon atoms, and C₁-C₈
 alkylsulfonyl or R₁ and R₂ are combined so that
 -NR₁R₂ together represent the residue of a
 10 saturated or unsaturated heterocyclic compound
 containing one secondary nitrogen atom; R₃ is
 selected from the group consisting of hydrogen, R₁,
 $\overset{\text{O}}{\parallel}$
 -C-R₁, -CH₂OCOR₁, -CH₂ONO₂, pyridyl, furyl,
 15 cyano, carbonyl, C₂-C₉ alkylcarbonyl, and
 dialkylcarbonyl wherein the alkyl portions each contain
 1 to 8 carbon atoms; R₁ is any radical encompassed by
 the definition of R₁ above; or a non-toxic
 pharmaceutically acceptable acid addition salt or oxide
 20 thereof, comprising reacting the acid chloride of a
 non-steroidal anti-inflammatory agent of the formula



25 with hydroxylamine followed by treatment with an
 aldehyde of the formula



30 and a secondary amine of the formula



anti-inflammatory drugs which would not be significantly ionized at physiological pH and which are reasonably stable, but which hydrolyze readily in vivo and yield upon hydrolysis only the parent non-steroidal anti-inflammatory drug and non-toxic, readily metabolized by-products.


SUMMARY OF THE INVENTION

It is one object of the present invention to provide prodrug forms of conventional non-steroidal anti-inflammatory agents which exhibit oral and topical anti-inflammatory activity when administered to warm-blooded animals and are characterized as being more readily bioavailable, less irritating to topical and gastric mucosal membranes and more permeable through topical membranes, e.g., ophthalmic membrane or skin, than are the non-steroidal anti-inflammatory drugs from which they are derived.

It is another object of the present invention to provide such prodrug forms of conventional anti-inflammatory compounds which, following administration, will "cleave" in such a manner as to enable the original parent moiety (indomethacin, sulindac, naproxen, or other known non-steroidal anti-inflammatory agent) to be released at its therapeutic site or sites of anti-inflammatory activity and to further permit the cleaved moiety(ies) unassociated with the parent moiety to be metabolized in a nontoxic fashion.

The foregoing objects are achieved by topically or orally administering to a warm-blooded animal afflicted with inflammation, a therapeutically

effective anti-inflammatory amount of a compound having the formula:



wherein $\text{R}-\text{C}-$ is the acyl residue of any non-steroidal
 O

15 anti-inflammatory agent containing a carboxylic acid function; R_1 and R_2 , which can be the same or different, each represent a member selected from the group consisting of alkyl of 1 to 20 carbon atoms; alkenyl of 2 to 20 carbon atoms; aryl of 6 to 10 carbon

20 atoms; cycloalkyl of 3 to 8 carbon atoms; cycloalkenyl of 4 to 8 carbon atoms; alkynyl of 2 to 20 carbon atoms; aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl, and alkynylaryl, wherein the alkyl, alkenyl, alkynyl, and aryl portions are defined as

25 above; and substituted derivatives of the above-defined alkyl, alkenyl, aryl, cycloalkyl, cycloalkenyl, alkynyl, aralkyl, alkaryl, aralkenyl, aralkynyl, alkenylaryl and alkynylaryl radicals, said derivatives having one or more substituents each of which are

30 selected from the group consisting of $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_1\text{-C}_8$ alkoxy, $\text{C}_1\text{-C}_8$ alkanoyl, $\text{C}_1\text{-C}_8$ alkanoyloxy, halo, $\text{C}_1\text{-C}_8$ haloalkyl, cyano, $\text{C}_2\text{-C}_9$ carbalkoxy, $\text{C}_1\text{-C}_8$ alkylthio,

1 4-phenylpiperidino, 2-methyl-1-pyrazolidinyl,
3-methyl-1-imidazolidinyl, 4-benzylpiperidino and
4-phenyl-1-piperazinyl.

5 7. A process according to Claim 4 wherein
the residue is that of an unsaturated one or two ring
system containing one or more double bonds and one or
more ring hetero atoms, optionally substituted with one
or more methyl groups.

10 8. A process according to Claim 7 wherein
the residue is selected from the group consisting of
1-imidazolyl, 1-pyrrolyl, 1-pyrazolyl, 1-indolinyl,
2-isindolinyl, 1-indolyl, 2-isindolyl,
15 1H-indazol-1-yl, 7-purinyl, pyrazolines, pyrrolines,
and imidazolines.

20 9. A process according to any one of Claims 1
to 8 wherein R_3 is hydrogen, alkyl, substituted alkyl
having one
or more halo substituents, alkyl-C(=O)- or aryl-C(=O)-.

25 10. The process according to Claim 1 comprising
preparing a compound selected from a group consisting of

(1) α -[1-(4'-chlorobenzoyl)-5-methoxy-
2-methylindol-3-yl]-N-(morpholino-
methyl)acetohydroxamic acid;

30 (2) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-(N',N'-diethylaminomethyl)-
acetohydroxamic acid;

35

- 1 (3) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(4-methylpiperazin-1-yl)-
methyl]acetohydroxamic acid;
- 5 (4) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-(piperidinomethyl)aceto-
hydroxamic acid;
- 10 (5) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(pyrrolidin-1-yl)methyl]-
acetohydroxamic acid;
- 15 (6) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-(N',N'-dicyclohexylamino-
methyl)acetohydroxamic acid;
- 20 (7) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(pyrrol-1-yl)methyl]aceto-
hydroxamic acid;
- 25 (8) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(indol-1-yl)methyl]aceto-
hydroxamic acid;
- 30 (9) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(isoindol-2-yl)methyl]aceto-
hydroxamic acid;
- 35 (10) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-[(purin-7-yl)methyl]aceto-
hydroxamic acid;
- (11) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-
indol-3-yl]-N-(N',N'-dimethylaminomethyl)-
acetohydroxamic acid;

- 1
(12) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-ind 1-3-yl]-N-(N',N'-diisopropylamino-methyl)acetohydroxamic acid;
- 5
(13) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dipentylaminomethyl)-acetohydroxamic acid;
- 10
(14) α -[1-(4'-chlorobenzoyl)-5-methoxy-2-methyl-indol-3-yl]-N-(N',N'-dioctylaminomethyl)-acetohydroxamic acid;
- 15
(15) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-(piperidinomethyl)acetohydroxamic acid;
- 20
(16) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-[(N'-benzyl-N'-phenyl)aminomethyl]acetohydroxamic acid;
- 25
(17) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-(morpholinomethyl)acetohydroxamic acid;
- 30
(18) α -{cis-5-fluoro-2-methyl-1-[4'-(methylsulfinyl)benzylidene]inden-3-yl}-N-[(imidazol-1-yl)methyl]acetohydroxamic acid;
- 35
(19) α -(6-methoxynaphthalen-2-yl)- α -methyl-N-(N',N'-diethylaminomethyl)acetohydroxamic acid;

- 1 (20) α -methyl- α -(3-phenoxy)phenyl-N-(piperidino-
methyl)acetohydroxamic acid;
- 5 (21) α -(methyl- α -(3-phenoxy)phenyl-N-[(N'-benzyl
-N'-phenyl)aminomethyl]acetohydroxamic
acid;
- 10 (22) α -methyl- α -(3-phenoxy)phenyl-N-(morpholino-
methyl)acetohydroxamic acid;
- (23) α -methyl- α -(3-phenoxy)phenyl-N-[(imidazol-
1-yl)methyl]acetohydroxamic acid;
- 15 (24) α -methyl- α -[4-(2'-methylpropyl)]phenyl-N-
(morpholinomethyl)acetohydroxamic acid;
- (25) α -methyl- α -[4-(2'-methylpropyl)]phenyl-N-
(piperidinomethyl)acetohydroxamic acid;
- 20 (26) α -[1-methyl-5-(p-toluoyl)pyrrol-2-yl]-N-
(N',N'-diethylaminomethyl)acetohydroxamic
acid;
- 25 (27) α -methyl- α -[4-(1'-oxoisindol-2'-yl)]phenyl
-N-(piperidinomethyl)acetohydroxamic
acid; and
- 30 (28) α -methyl- α -[4-(1'-oxoisindol-2'-yl)]phenyl
-N-(morpholinomethyl)acetohydroxamic acid.